tetano
Editor, Senior Moderator
J Med Virol
. 2023 Sep;95(9):e29089.
doi: 10.1002/jmv.29089. Examination of autoantibodies to type I interferon in patients suffering from long COVID
Kristoffer Skaalum Hansen[SUP] 1 2 [/SUP], Sofie Eg Jørgensen[SUP] 1 3 [/SUP], Morten Kelder Skouboe[SUP] 1 3 [/SUP], Jane Agergaard[SUP] 1 2 [/SUP], Berit Schiøttz-Christensen[SUP] 1 4 [/SUP], Line Khalidan Vibholm[SUP] 1 [/SUP], Martin Tolstrup[SUP] 1 2 [/SUP], Lars Østergaard[SUP] 1 2 [/SUP], Steffen Leth[SUP] 1 2 5 [/SUP], Trine H Mogensen[SUP] 1 3 [/SUP]
Affiliations
Long COVID (LC) is an emerging global health concern. The underlying mechanism and pathophysiology remain unclear. Presence of neutralizing autoantibodies against type 1 interferons (IFN) has been established as a predictor of critical COVID-19. We hypothesized that persistent autoimmune activity with autoantibodies against type 1 IFN may contribute to symptoms in patients with LC. Plasma samples and clinical information were obtained from a Danish LC cohort consisting of adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Information on symptoms and quality of life was derived from an LC-specific questionnaire and the EQ-5D-5L questionnaire. Detection of type 1 IFN autoantibodies in plasma were performed by ELISA. Samples collected between June, 2020, and September, 2021, from 279 patients were analyzed and compared to a control group of 94 individuals with prior mild SARS-CoV-2 infection who did not develop LC symptoms. In total, five LC patients (1.8%) and 3 (3.2%) of the controls had detectable circulating type 1 IFN autoantibodies. Collectively, prevalence of autoantibodies against type 1 IFN subtypes in our LC cohort were primarily driven by men and did not exceed the prevalence in controls. Thus, in our cohort, anti-type I IFN autoantibodies are unlikely to drive LC symptoms.
Keywords: autoantibodies; autoimmunity; immunology; interferon; long COVID.
. 2023 Sep;95(9):e29089.
doi: 10.1002/jmv.29089. Examination of autoantibodies to type I interferon in patients suffering from long COVID
Kristoffer Skaalum Hansen[SUP] 1 2 [/SUP], Sofie Eg Jørgensen[SUP] 1 3 [/SUP], Morten Kelder Skouboe[SUP] 1 3 [/SUP], Jane Agergaard[SUP] 1 2 [/SUP], Berit Schiøttz-Christensen[SUP] 1 4 [/SUP], Line Khalidan Vibholm[SUP] 1 [/SUP], Martin Tolstrup[SUP] 1 2 [/SUP], Lars Østergaard[SUP] 1 2 [/SUP], Steffen Leth[SUP] 1 2 5 [/SUP], Trine H Mogensen[SUP] 1 3 [/SUP]
Affiliations
- PMID: 37698062
- DOI: 10.1002/jmv.29089
Long COVID (LC) is an emerging global health concern. The underlying mechanism and pathophysiology remain unclear. Presence of neutralizing autoantibodies against type 1 interferons (IFN) has been established as a predictor of critical COVID-19. We hypothesized that persistent autoimmune activity with autoantibodies against type 1 IFN may contribute to symptoms in patients with LC. Plasma samples and clinical information were obtained from a Danish LC cohort consisting of adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Information on symptoms and quality of life was derived from an LC-specific questionnaire and the EQ-5D-5L questionnaire. Detection of type 1 IFN autoantibodies in plasma were performed by ELISA. Samples collected between June, 2020, and September, 2021, from 279 patients were analyzed and compared to a control group of 94 individuals with prior mild SARS-CoV-2 infection who did not develop LC symptoms. In total, five LC patients (1.8%) and 3 (3.2%) of the controls had detectable circulating type 1 IFN autoantibodies. Collectively, prevalence of autoantibodies against type 1 IFN subtypes in our LC cohort were primarily driven by men and did not exceed the prevalence in controls. Thus, in our cohort, anti-type I IFN autoantibodies are unlikely to drive LC symptoms.
Keywords: autoantibodies; autoimmunity; immunology; interferon; long COVID.